OncoMatch

OncoMatch/Clinical Trials/NCT04532281

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Is NCT04532281 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Murine CD19 CAR-T cells for acute lymphoblastic leukemia.

Early Phase 1RecruitingZhejiang UniversityNCT04532281Data as of Jun 2026Location: China

Treatment: Murine CD19 CAR-T cellsA Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Murine CD19 CAR-T cells

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: CD19 positive

CD19+ B-ALL

Required: CD19 positive

B-NHL (all listed subtypes are B-cell lymphomas and presumed CD19+ for CAR-T eligibility)

Excluded: BCR-ABL1 fusion

Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: car-t cell therapy

Lab requirements

Kidney function

creatinine ≤ 176.8 umol/l

Liver function

total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal

Cardiac function

echocardiogram shows left ventricular ejection fraction (lvef) ≥ 50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04532281 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior car-t cell therapy disqualifies patients from enrollment.

Does this trial require CD19?

Yes, CD19 positive is a required biomarker for enrollment.

Does this trial require CD19?

Yes, CD19 positive is a required biomarker for enrollment.

Are patients with BCR-ABL1 alterations eligible?

No. BCR-ABL1 fusion is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify